Warfarin and allergy medication can be a tricky combination to navigate safely. Warfarin is a widely used anticoagulant with a narrow therapeutic window, meaning even small changes in medication can shift the INR outside its target range — raising the risk of bleeding or clotting. During hay fever season, many patients reach for over-the-counter allergy remedies without realising some may interact with their anticoagulant. This article explains which allergy treatments are considered lower risk, which require caution, and when to seek advice from your GP or anticoagulation clinic to keep your INR stable.

Can You Take Allergy Medication with Warfarin?

Warfarin is a widely prescribed anticoagulant used to prevent blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It works by inhibiting vitamin K-dependent clotting factors, and its therapeutic effect is measured using the International Normalised Ratio (INR). Because warfarin has a narrow therapeutic window, even modest changes in diet, illness, or medication can shift the INR outside the target range — increasing the risk of either bleeding or clotting. This is reflected in the warfarin sodium Summary of Product Characteristics (SmPC) and the British National Formulary (BNF), both of which highlight the importance of INR monitoring whenever any new medicine is introduced or stopped.

Allergy medications are among the most commonly used over-the-counter (OTC) treatments in the UK, particularly during hay fever season. Many patients on warfarin assume that OTC allergy remedies are automatically safe because they do not require a prescription. This is a misconception that can carry real clinical risk. Some allergy treatments — including certain antihistamines, decongestants, and herbal remedies — may interact with warfarin or alter its anticoagulant effect.

It is also worth noting that some OTC combination allergy and cold products contain paracetamol. Whilst paracetamol is generally preferred over aspirin or ibuprofen in patients on warfarin, repeated use at higher doses (for example, more than 2 g per day for several consecutive days) has been associated with a rise in INR. Patients taking such products regularly should inform their anticoagulation team and consider an additional INR check.

Interactions do not always mean a medication is completely off-limits. Rather, they signal the need for caution, closer INR monitoring, and, in some cases, a conversation with a GP or anticoagulation clinic before starting any new treatment. Patients should always inform their anticoagulation team of any new medication, including OTC products and supplements, to ensure their INR remains stable and their safety is maintained.

Antihistamines and Warfarin: Known Interactions

Antihistamines are the cornerstone of allergy management and are broadly divided into first-generation (sedating) and second-generation (non-sedating) types. In terms of warfarin interaction, the evidence base is limited for most agents, and it is important not to overstate the risk or treat all antihistamines as equivalent.

First-generation antihistamines, such as chlorphenamine (Piriton), have occasionally been mentioned in case reports in the context of anticoagulant therapy, but robust clinical trial data confirming a consistent, clinically significant interaction with warfarin are lacking. The BNF does not list chlorphenamine as a specific, established interacting agent with warfarin. As with any new medicine, caution and INR awareness are appropriate.

Second-generation antihistamines, including cetirizine, loratadine, and fexofenadine, are generally considered to carry a low likelihood of clinically significant INR change. Isolated case reports have noted INR fluctuations with some agents, but these are rare and the evidence base is very limited. The key principle from UK guidance (BNF, MHRA) is not that antihistamines are specifically prohibited, but that INR should be monitored whenever any new medicine — including an antihistamine — is started or stopped.

Fexofenadine has minimal involvement with hepatic cytochrome P450 enzymes and is often considered a practical option; it is available OTC in the UK at 120 mg. INR monitoring after initiation remains advisable regardless of which antihistamine is chosen.

Topical options such as sodium cromoglicate eye drops or azelastine eye drops offer very low systemic absorption and are worth considering for patients with predominantly ocular allergy symptoms, as they are unlikely to affect INR.

Key points to be aware of:

• The primary UK guidance is to monitor INR with any new medicine, rather than to prohibit specific antihistamines

• Second-generation antihistamines (cetirizine, loratadine, fexofenadine) are generally preferred for allergy management and carry a low likelihood of significant INR disruption

• Topical ocular antihistamines or sodium cromoglicate eye drops offer a minimal-systemic-exposure alternative for eye symptoms

• Always check with a pharmacist or consult the BNF before starting any antihistamine alongside warfarin, and arrange an INR check shortly after

Allergy Treatments That May Affect Your INR

Beyond antihistamines, a broader range of allergy-related treatments can influence INR stability. Understanding these is essential for patients managing seasonal or perennial allergies whilst on anticoagulation therapy.

Decongestants — oral preparations such as pseudoephedrine and phenylephrine are commonly found in combination cold and allergy products. They do not directly interact with warfarin's anticoagulant mechanism in a clinically established way, but combination products containing aspirin or ibuprofen — both of which affect platelet function and gastric mucosa — pose a direct bleeding risk when taken alongside warfarin and should be avoided. Topical nasal decongestants (for example, xylometazoline or oxymetazoline nasal sprays) have minimal systemic absorption and may be used for short courses (no more than seven days) to avoid rebound congestion; they are a preferable option to oral decongestants where short-term nasal relief is needed.

Paracetamol in combination products deserves specific mention. Many OTC allergy and cold remedies contain paracetamol. Whilst paracetamol is generally safer than NSAIDs in patients on warfarin, repeated use at doses above approximately 2 g per day for several days has been associated with INR elevation. Patients should check product labels carefully and inform their anticoagulation team if using paracetamol-containing products regularly.

Nasal corticosteroid sprays, such as fluticasone propionate (Flixonase) or fluticasone furoate (Avamys), and beclometasone dipropionate (Beconase), are widely used for allergic rhinitis and are generally considered safe with warfarin when used as directed. Systemic absorption is minimal at standard doses, meaning they are unlikely to affect INR significantly. NICE Clinical Knowledge Summaries (CKS) support intranasal corticosteroids as a first-line treatment for moderate-to-severe allergic rhinitis, making them a clinically appropriate option for many patients on anticoagulation.

Herbal and complementary remedies present a more significant concern, though the evidence for specific interactions varies and should be interpreted cautiously. Based on available data and guidance from the Specialist Pharmacy Service (SPS):

• Echinacea — some evidence suggests possible effects on cytochrome P450 enzymes; caution is advised and it is not routinely recommended alongside warfarin

• Chamomile — contains natural coumarin compounds and may potentiate warfarin's anticoagulant effect; best avoided

• Butterbur — data are very limited; if ever considered, only pyrrolizidine alkaloid (PA)-free preparations should be used due to hepatotoxicity risk, and use alongside warfarin is not routinely recommended

Patients should be explicitly advised that 'natural' does not mean safe in the context of anticoagulation therapy. Any herbal or complementary product should be discussed with a pharmacist or GP before use.

Safer Allergy Relief Options for People on Warfarin

Whilst no allergy treatment is entirely without consideration for patients on warfarin, several options are associated with a lower risk of clinically significant INR disruption and are broadly supported by UK clinical guidance.

Intranasal corticosteroid sprays remain the preferred first-line treatment for allergic rhinitis according to NICE CKS. Preparations such as beclometasone dipropionate nasal spray (Beconase) are available OTC and have a well-established safety profile. Their minimal systemic absorption makes them unlikely to interact with warfarin in a meaningful way, making them a practical and effective choice.

Second-generation antihistamines, particularly fexofenadine (available OTC at 120 mg in the UK), are generally considered lower risk due to their limited involvement with hepatic cytochrome P450 enzymes. Where oral antihistamine therapy is needed, fexofenadine may be a preferable option, though INR monitoring following initiation remains advisable. Patients should avoid combination products that include aspirin or ibuprofen; check labels carefully for hidden NSAIDs or paracetamol, particularly in multi-symptom cold and allergy preparations.

Topical options with minimal systemic absorption are worth considering:

• Sodium cromoglicate eye drops — suitable for allergic conjunctivitis; very low systemic exposure and unlikely to affect INR

• Azelastine eye drops — an antihistamine eye drop with minimal systemic absorption

• Short-course topical nasal decongestants (e.g., xylometazoline) — for up to seven days only; avoid prolonged use due to rebound congestion

• Nasal ipratropium — may help with rhinorrhoea; minimal systemic absorption

Non-pharmacological measures can also play a meaningful role in reducing allergy symptom burden:

• Wearing wraparound sunglasses outdoors to reduce pollen exposure

• Showering and changing clothes after time spent outside

• Keeping windows closed during high pollen counts

• Using saline nasal rinses to clear allergens from the nasal passages

• Monitoring pollen forecasts via the Met Office or NHS resources

These strategies, combined with carefully selected pharmacological treatments, can help patients manage their allergy symptoms effectively without compromising the stability of their anticoagulation.

When to Seek Advice from Your GP or Anticoagulation Clinic

Patients on warfarin should be encouraged to adopt a proactive approach to any change in their medication regimen, including the addition of allergy treatments. There are specific circumstances in which prompt advice from a GP or anticoagulation clinic is particularly important.

Seek urgent emergency help (call 999 or go to A&E) if you experience:

• Heavy or prolonged bleeding that will not stop

• Vomiting blood or coughing up blood

• Black, tarry, or blood-stained stools

• Sudden severe headache, confusion, or difficulty speaking

• Head injury (even if it seems minor)

• Sudden severe back or abdominal pain

These may be signs of serious bleeding and require immediate medical attention. Do not wait for a routine INR appointment.

Contact your GP or anticoagulation clinic if:

• You are considering starting any new OTC allergy medication, including antihistamines, decongestants, or nasal sprays

• You have recently started a new allergy treatment and notice unusual bruising, prolonged bleeding from minor cuts, blood in urine, or unexpected nosebleeds

• Your INR result is outside your target range following the introduction of a new medication

• You are considering using any herbal or complementary remedy for allergy symptoms

• Your allergy symptoms are severe or poorly controlled, as this may indicate a need for specialist review

It is also worth noting that acute intercurrent illness — such as fever, diarrhoea, vomiting, or acute infection — can transiently affect INR, as can changes in liver or thyroid function, or a significant reduction in dietary vitamin K intake. These factors can alter INR independently of any new medication taken.

Patients should never stop warfarin without medical advice, even if they are concerned about a potential interaction. The risks of untreated anticoagulation (such as stroke or thromboembolism) may far outweigh the risks of a managed interaction. The anticoagulation team is best placed to advise on the safest course of action and may recommend a short-term increase in INR monitoring frequency when a new allergy treatment is introduced.

If you or your healthcare professional suspects that a medicine — including an OTC allergy product — has caused an adverse reaction, this can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Managing Allergies Safely While on Anticoagulation Therapy

Living with both a condition requiring anticoagulation and seasonal or perennial allergies requires a thoughtful, informed approach. With the right guidance and monitoring, it is entirely possible to manage allergy symptoms effectively without compromising anticoagulation safety.

The foundation of safe management is open communication with your healthcare team. This includes your GP, anticoagulation nurse or clinic, and community pharmacist — all of whom can provide tailored advice based on your current INR, target range, and overall health status. Pharmacists are an accessible and often underutilised resource; they can check for interactions before you purchase any OTC product and advise on the most appropriate formulation.

Practical steps for safe allergy management on warfarin:

• Keep an up-to-date list of all medications, including OTC products, herbal remedies, and supplements, to share with your healthcare team

• Do not assume that OTC or 'natural' products are automatically safe — always check with a pharmacist or GP first

• If you start a new allergy treatment, consider requesting an additional INR check within one to two weeks

• Follow NICE-recommended first-line treatments such as intranasal corticosteroids where appropriate

• Check combination product labels carefully for aspirin, ibuprofen, or paracetamol, and discuss regular paracetamol use with your anticoagulation team

• Report any new or unusual symptoms promptly — particularly those that may suggest bleeding — and seek emergency help without delay if you experience any of the serious warning signs described above

• Report any suspected adverse reactions to a medicine via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk

Patients who are well-informed and engaged with their anticoagulation management are better placed to make safe decisions. The goal is not to avoid all allergy treatment, but to choose wisely, monitor carefully, and communicate openly — ensuring both allergy relief and anticoagulation safety are maintained throughout the year.

Frequently Asked Questions